Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT EV-to-EBITDA is 5.41 as of Jul. 23, 2026, which is 3% above its 10-year median of 5.25. The stock has 8 warning signs investors should review. Among 743 Drug Manufacturers companies, Vitura Health ranks better than 85.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vitura Health's enterprise value is A$28.6 Mil.
Vitura Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.3 Mil. Therefore, Vitura Health's EV-to-EBITDA for today is 5.41.
The historical rank and industry rank for Vitura Health's EV-to-EBITDA or its related term are showing as below:
ASX:VIT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -85.73 Med: 5.25 Max: 39.15
Current: 5.41
During the past 7 years, the highest EV-to-EBITDA of Vitura Health was 39.15. The lowest was -85.73. And the median was 5.25.
ASX:VIT's EV-to-EBITDA is ranked better than 85.46% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.02
vs ASX:VIT: 5.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Vitura Health (ASX:VIT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vitura Health's PE Ratio (TTM) for today is calculated as:
Vitura Health's share price for today is A$0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitura Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vitura Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vitura Health's EV-to-EBITDA falls into.
Vitura Health's current Enterprise Value is A$28.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitura Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a EV-to-EBITDA of 5.41 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vitura Health. This is near median its historical median of 5.25. According to the industry distribution chart, Vitura Health ranks #108 out of 743 companies in the Drug Manufacturers industry, placing it in the top 14.5%.
Is Vitura Health's EV-to-EBITDA too high?
Vitura Health's current EV-to-EBITDA of 5.41 is near median its 10-year median of 5.25. The Drug Manufacturers industry median EV-to-EBITDA is 13.02. Vitura Health's value of 5.41 is 58.4% below this industry median. Based on the distribution chart, Vitura Health ranks #108 out of 743 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Vitura Health's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #108 out of 743 companies for EV-to-EBITDA. This places Vitura Health in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.02. Vitura Health's value of 5.41 is 58.4% below this benchmark. While the company's 10-year median is 5.25 vs. the industry median of 13.02, Vitura Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current EV-to-EBITDA of 5.41 is 58.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vitura Health. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current EV-to-EBITDA is 5.41, which is near median its own 10-year median of 5.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 70% below its estimated fair value. The current EV-to-EBITDA is 5.41, which is near median its 10-year median of 5.25 and 58.4% below the Drug Manufacturers industry median of 13.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current EV-to-EBITDA is 5.41 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
